Narya Bio
Agent55Agent Readiness: 55/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust61Data Trust: 61/100. Above median. Measured by StartupHub.ai. Median 61.Narya Bio is developing novel therapeutic antibodies for challenging diseases.
About
Narya Bio is a biotechnology company focused on developing next-generation therapeutic antibodies. They leverage advanced computational and biological approaches to design antibodies with improved efficacy and safety profiles for diseases that are currently difficult to treat.
Listed competitors
Also in this space
Leveraging the adaptive immune system to diagnose and treat disease.
Shares Biotech, Genomics
Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.
Shares Biotech, Genomics
AI-powered platform for personalized cell therapy development and manufacturing.
Shares Biotech, Drug Discovery
Advance every cancer decision.
Shares Biotech, Drug Discovery
PFx Biotech is developing a novel platform for the discovery and development of protein-based therapeutics.
Shares Biotech, Drug Discovery
Biosynthesis of cannabinoids and psychedelics using advanced biotechnology.
Shares Biotech, Drug Discovery
Key facts
- Website
- narya.ai
- Headquarters
- Israel
- Founded
- 2022
- Employees
- 8
- Business model
- B2B
Tech stack
Detected on narya.ai, last scanned 20 Oct 2026. Run your own scan
- Payments
- Stripe
- CDN
- Cloudflare
- Email provider
- Google Workspace
Narya Bio scores 24. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Narya Bio trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Narya Bio is 61 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How many employees does Narya Bio have?
Narya Bio has approximately 8 people on record.
